CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.8158
5.68%
Market Trading Hours* (UTC) Opens on Thursday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.0184
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 1.9358
Open 1.8558
1-Year Change 231.39%
Day's Range 1.7958 - 1.9158
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 17, 2024 1.8258 -0.0600 -3.18% 1.8858 1.9158 1.7958
Jul 16, 2024 1.9358 0.0200 1.04% 1.9158 1.9658 1.8858
Jul 15, 2024 1.8958 0.0200 1.07% 1.8758 1.9258 1.8158
Jul 12, 2024 1.8558 0.0600 3.34% 1.7958 1.8858 1.7658
Jul 11, 2024 1.8258 0.0100 0.55% 1.8158 1.8658 1.7858
Jul 10, 2024 1.7958 0.0200 1.13% 1.7758 1.7958 1.7158
Jul 9, 2024 1.7958 0.0800 4.66% 1.7158 1.8158 1.7158
Jul 8, 2024 1.7358 0.0100 0.58% 1.7258 1.7458 1.6458
Jul 5, 2024 1.6958 0.1000 6.27% 1.5958 1.6958 1.5558
Jul 3, 2024 1.6258 0.0400 2.52% 1.5858 1.6858 1.5758
Jul 2, 2024 1.6058 0.0000 0.00% 1.6058 1.7358 1.5958
Jul 1, 2024 1.6158 0.1000 6.60% 1.5158 1.6258 1.4858
Jun 28, 2024 1.5158 0.0200 1.34% 1.4958 1.5758 1.3958
Jun 27, 2024 1.4058 0.1400 11.06% 1.2658 1.4158 1.2358
Jun 26, 2024 1.2558 0.0500 4.15% 1.2058 1.2958 1.1458
Jun 25, 2024 1.1658 -0.0700 -5.66% 1.2358 1.2858 1.1658
Jun 24, 2024 1.2458 -0.1000 -7.43% 1.3458 1.3558 1.2058
Jun 21, 2024 1.3258 0.0300 2.32% 1.2958 1.3358 1.2758
Jun 20, 2024 1.2758 -0.0700 -5.20% 1.3458 1.3658 1.2558
Jun 18, 2024 1.3658 0.0200 1.49% 1.3458 1.4158 1.3458

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Ocugen, Inc. Company profile

Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine. 

Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.

Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. 

For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.

The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).

The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD). 

Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.

Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.

Ocugen is headquartered in Malvern, Pennsylvania.

Industry: Biotechnology & Medical Research (NEC)

11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US

People also watch

US100

19,932.90 Price
+0.570% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

3,470.39 Price
+1.510% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,466.64 Price
+0.280% 1D Chg, %
Long position overnight fee -0.0196%
Short position overnight fee 0.0114%
Overnight fee time 21:00 (UTC)
Spread 0.30

XRP/USD

0.59 Price
-7.170% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading